Work

Phase Ib dose-escalation trial of the AKT inhibitor (AKTi) MK2206 in combination with paclitaxel (P) and trastuzumab (H) in patients (pts) with HER2-overexpressing (HER2+) cancer.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.2605

Authors: Amy Jo Chien, Thach-Giao Truong, Michelle E. Melisko, Mark M. Moasser, Robin Katie Kelley, Michael Korn, Andrew H. Ko, Norma Pantoja, Anne Reinert, Jennifer A. Grabowsky, Mark Jesus M Magbanua, Hope S. Rugo, Pamela N. Munster

Institutions: UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2601638583

Cites:

Cited by: 5

Related to: 10